zalcitabine has been researched along with Polyneuropathies in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lau, T; Rice, AS; Smith, MT; Wallace, VC; Wyse, BD | 1 |
| Karandreas, N; Kokotis, PI; Konstantinou, K; Kontos, AN; Kordossis, T; Panayiotakopoulos, GD; Skopelitis, EE | 1 |
2 other study(ies) available for zalcitabine and Polyneuropathies
| Article | Year |
|---|---|
Analgesic efficacy of small-molecule angiotensin II type 2 receptor antagonists in a rat model of antiretroviral toxic polyneuropathy.
Topics: Analgesics; Angiotensin II Type 2 Receptor Blockers; Animals; Anti-HIV Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Exploratory Behavior; Hot Temperature; Hyperalgesia; Imidazoles; Male; Neuralgia; Polyneuropathies; Pyridines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Sciatic Neuropathy; Time Factors; Touch; Zalcitabine | 2014 |
Distal sensory polyneuropathy in HIV-positive patients in the HAART era: an entity underestimated by clinical examination.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; Electrophysiology; Female; HIV Infections; Humans; Male; Middle Aged; Polyneuropathies; Prevalence; Reverse Transcriptase Inhibitors; Risk Factors; Stavudine; Zalcitabine | 2006 |